anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
anlotinib alters tumor immune microenvironment by downregulating PD-L1 expression on vascular endothelial cells
Authors
Keywords
-
Journal
Cell Death & Disease
Volume 11, Issue 5, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-05-04
DOI
10.1038/s41419-020-2511-3
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Endothelium structure and function in kidney health and disease
- (2019) Noemie Jourde-Chiche et al. Nature Reviews Nephrology
- PD-L1 Expression Is Associated With VEGFA and LADC Patients' Survival
- (2019) Shaochuan Liu et al. Frontiers in Oncology
- Combined low densities of FoxP3+ and CD3+ tumor-infiltrating lymphocytes identify stage II colorectal cancer at high risk of progression
- (2019) Tommaso Cavalleri et al. Cancer Immunology Research
- Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
- (2019) Ai‐Ping Zhou et al. ONCOLOGIST
- PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer
- (2019) Yanhui Chen et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)
- (2018) Baohui Han et al. BRITISH JOURNAL OF CANCER
- Regulation and Function of the PD-L1 Checkpoint
- (2018) Chong Sun et al. IMMUNITY
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Stromal PD-1 / PD-L1 expression predicts outcome in colon cancer patients
- (2018) Jacqueline Wyss et al. Clinical Colorectal Cancer
- Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
- (2018) Guoshuang Shen et al. Journal of Hematology & Oncology
- Immunomodulation of Tumor Vessels: It Takes Two to Tango
- (2018) Anna Johansson-Percival et al. TRENDS IN IMMUNOLOGY
- IFNγ-activated dermal lymphatic vessels inhibit cytotoxic T cells in melanoma and inflamed skin
- (2018) Ryan S. Lane et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Novel Role for PD-1:PD-L1 as Mediator of Pulmonary Vascular Endothelial Cell Functions in Pathogenesis of Indirect ARDS in Mice
- (2018) Joanne Lomas-Neira et al. Frontiers in Immunology
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Human umbilical vein endothelial cells promote the inhibitory activation of CD4+CD25+Foxp3+ regulatory T cells via PD-L1
- (2016) Wei-Jun Chen et al. ATHEROSCLEROSIS
- Pretreatment of RPE Cells with Lutein Can Mitigate Bevacizumab-Induced Increases in Angiogenin and bFGF
- (2016) Natàlia Vilà et al. OPHTHALMIC RESEARCH
- PD-L1 expression as a potential predictive biomarker
- (2015) Alberto Fusi et al. LANCET ONCOLOGY
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Human brain endothelial cells endeavor to immunoregulate CD8 T cells via PD-1 ligand expression in multiple sclerosis
- (2011) Camille L Pittet et al. Journal of Neuroinflammation
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started